The field of oncology has seen significant advancements in recent years, particularly in the area of targeted therapies. These treatments, designed to more precisely attack cancer cells, are transforming our approach to cancer care.
Unlike traditional chemotherapy, which indiscriminately affects all rapidly dividing cells, targeted therapies are designed to interfere with specific molecules needed for tumor growth and progression. By blocking these molecules, targeted therapies can halt the growth and spread of cancer while minimizing damage to healthy cells.
There are several types of targeted therapies currently in use, including monoclonal antibodies, small molecule drugs, and cancer vaccines. Monoclonal antibodies are designed to bind to specific targets on the surface of cancer cells, while small molecule drugs can penetrate the cell membrane to interact with targets inside the cell. Cancer vaccines, on the other hand, stimulate the immune system to attack cancer cells.
Targeted therapies have shown promise in a variety of cancer types, including breast, lung, colorectal, and melanoma. For example, the monoclonal antibody trastuzumab has significantly improved outcomes for patients with HER2-positive breast cancer. Similarly, the small molecule drug imatinib has revolutionized the treatment of chronic myeloid leukemia.
While targeted therapies have already had a significant impact on cancer care, there is still much to learn about how best to use these drugs. Ongoing research is focused on identifying new therapeutic targets, developing more effective drugs, and determining which patients are most likely to benefit from targeted therapies.
Targeted therapies represent a significant advancement in oncology, offering the potential for more effective and less toxic treatments. As our understanding of cancer biology continues to grow, it is anticipated that the use of targeted therapies will become increasingly prevalent in cancer care.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation